Articles

Results 1 to 5 of 19


A Look at AIA § 3(n)(2): Part Two of a Two-Part Series on AIA § 3(n) Effective Filing Date Provisions

USA - September 24 2021 Interpreting the language of the America Invents Act (AIA) remains an exciting challenge. The effective date provisions of the AIA transition…

M. Paul Barker, Adriana L. Burgy, Thomas L. Irving, Stacy Lewis†, Amanda K. Murphy, Jill K. MacAlpine, Ph.D.

AIA § 3(n) Effective Filing Date Provisions Part I: A Look at PGR Eligibility

USA - July 16 2021 Interpreting the language of the America Invents Act (AIA) continues to be a fascinating exercise. The effective date provisions of the AIA…

M. Paul Barker, Adriana L. Burgy, Thomas L. Irving, Stacy Lewis, Amanda K. Murphy, Jill K. MacAlpine, Ph.D.

Got Pharmaceutical Means-Plus-Function Claims?

USA - August 17 2020 Almost seventy years ago, Congress passed the 1952 Patent Act, which included 35 U.S.C. §112(6), the first statutory language describing…

Adriana L. Burgy, Thomas L. Irving, Stacy Lewis, Melanie Magdun, Jill K. MacAlpine, Ph.D.

Proposed Revisions to Form 3542 with Explanations

USA - July 8 2020 In 1978, the FDA Commissioner announced the FDA’s intent to provide a list of all prescription drug products approved by the FDA for safety and…

Justin J. Hasford, Thomas L. Irving, Stacy Lewis, Jill K. MacAlpine, Ph.D.

A Belated Lesson in How to Avoid a Finding of Obviousness Based Upon Inherent Disclosure

USA - January 13 2020 The District Court of Delaware held Persion’s claims invalid for obviousness and lack of written description. The Federal Circuit affirmed the…

Adriana L. Burgy, Thomas L. Irving, Stacy Lewis